Drug Approval | September 10, 2025
FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
The facility has been designed with a dual focus on efficiency and sustainability
The payment is in accordance with the agreed contractual terms
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Subscribe To Our Newsletter & Stay Updated
